Weight Regain After Bariatric Surgery: Is the Semaglutide Era Beginning?
In this article
Secondary Failure in Metabolic Surgery: Integrating Semaglutide After Bariatric Surgery and Clinical Algorithms
The cessation or reversal of weight loss after MBS is clinically considered in two groups. The first is a condition in which less of the initial excess weight is lost than expected after surgery, termed a suboptimal clinical response; the second is an uncontrolled rise in weight after the lowest postoperative weight has been reached (the nadir point/nadir weight), known as weight regain.
ANATOMICAL AND BIOLOGICAL DYNAMICS OF SECONDARY POSTOPERATIVE FAILURE
- Neuroendocrine Adaptation: After surgical resection (for example, sleeve gastrectomy), a sudden decrease in plasma ghrelin levels and a physiological increase in GLP-1 and PYY levels are observed. However, from postoperative months 12-18 onward, homeostatic mechanisms come into play, reducing energy expenditure (metabolic slowing) and stimulating appetite centers again.
- Anatomical Changes: Gradual stretching of the gastric pouch, enlargement of the gastrojejunal anastomotic stoma (after Roux-en-Y gastric bypass), or adaptation of the pyloric mechanism may reduce the patient's sense of satiety.
- Behavioral and Environmental Factors: A shift toward consuming high-calorie liquids/snacks (grazing), physical inactivity, and psychological recurrence of preoperative eating disorders (binge eating, emotional hunger).
- Biological Limits: Although obesity surgery provides mechanical restriction and malabsorption, it cannot completely eliminate chronic inflammation in adipose tissue or hypothalamic leptin resistance.
Clinical Definition: When Can We Speak of Genuine Failure?
Although different thresholds are used to define surgical failure in the literature, current consensus and the BARI-STEP protocol accept loss of less than 20% of initial total body weight, or regaining at least 10-15% of the excess weight lost after reaching nadir weight, as clinical warning thresholds, provided that at least 12 months have passed since surgery.
Conducted at the National Diabetes and Obesity Centre of University College London Hospitals (UCLH) by Dr. Janine Makaronidis and her team, the BARI-STEP trial is the first double-blind, randomized, placebo-controlled clinical trial testing weekly semaglutide 2.4 mg in patients who underwent bariatric surgery and experienced inadequate weight outcomes. It provided crucial data for understanding how patients who have undergone surgery respond hormonally to pharmacotherapy.
BARI-STEP — PATIENT PROFILE AND PROTOCOL DETAILS
- Sample and Centers: 70 adult patients followed at two major academic centers in the United Kingdom (UCLH and Homerton University Hospital).
- Inclusion Criteria: Having undergone Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) at least 12 months earlier; having lost <20% of total weight since surgery (inadequate response) OR having experienced substantial weight gain after reaching nadir weight.
- Randomization and Dosage: Patients were randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg (starting at 0.25 mg and increased using the standard 4-week escalation protocol) or matching placebo.
- Multidisciplinary Support: Both arms received structured behavioral and nutritional support delivered by bariatric dietitians, targeting a daily deficit of 500 kcal.
- Assessment Period: 68 weeks of active treatment follow-up.
| Parameter (Week 68 Results) | Semaglutide 2.4 mg Group (n=34) | Placebo + Lifestyle (n=29) | Treatment Difference / Statistical Significance |
|---|---|---|---|
| Mean Body Weight Change (%) | -%18.0 | +%0.4 | Net Difference: - 19.18% (P < 0.001) |
| Proportion of Patients Losing ≥ 10% of Their Weight | %85.3 | %6.9 | Odds Ratio: 62.1 (P < 0.001) |
| Proportion of Patients Losing ≥ 15% of Their Weight | %61.8 | %6.9 | P < 0.001 |
| Proportion of Patients Losing ≥ 20% of Their Weight | %47.1 | %3.4 | P < 0.001 |
| Change in Systolic Blood Pressure (mmHg) | -6.7 mmHg | -1.2 mmHg | P = 0.012 |
| Change in Fasting Plasma Glucose (mg/dL) | -11.3 mg/dL | +1.5 mg/dL | P = 0.003 |
When achieving additional weight loss in patients who have undergone bariatric surgery, the most feared clinical complication is the development of sarcopenic obesity . These patients are already prone to loss of muscle mass (lean mass) because of malabsorption and impaired protein absorption. There is concern that medical agents may compromise muscle tissue.
🔬 BODY COMPOSITION AND SELECTIVITY FOR ADIPOSE TISSUE
According to advanced body-composition analysis data from the BARI-STEP trial, the main component of weight loss achieved in the semaglutide group was reported to be body fat rather than muscle tissue. The absence of a clinically significant decrease in muscle mass suggests that semaglutide, when used together with appropriate protein supplementation and structured lifestyle management, may help preserve muscle tissue without provoking sarcopenia after bariatric surgery.
One of the questions clinicians are most interested in is whether the drug is more effective in patients with Roux-en-Y gastric bypass (RYGB), which completely changes the anatomy, or in patients with sleeve gastrectomy (SG), which relatively preserves anatomical continuity.
PHARMACOKINETIC EFFECTS OF ANATOMICAL VARIATIONS
- Sleeve Gastrectomy: In these patients, the ghrelin-producing fundus has been resected, but intestinal passage remains normal. Semaglutide helps restore early satiety by slowing gastric emptying again in the sleeve stomach.
- Roux-en-Y Gastric Bypass (RYGB): In this anatomy, the gastric pouch is small and food passes directly into the jejunum (rapid intestinal transit). RYGB patients already have high endogenous GLP-1 levels after surgery. However, receptor desensitization to these high levels may develop over time. Exogenous semaglutide 2.4 mg can also produce a strong response in patients with bypass by providing a pharmacological concentration sufficient to overcome this desensitization.
- Absorption Dynamics: Because semaglutide is administered as a subcutaneous injection (under the skin), it is not affected by the intestinal malabsorption caused by bariatric surgery. This allows the drug to provide stable bioavailability regardless of the type of surgery.
The safety of high-dose GLP-1 receptor agonists in individuals with altered gastrointestinal anatomy was carefully examined. In particular, the course of conditions common after bariatric surgery, such as dumping syndrome, reactive hypoglycemia, and chronic nausea, was a critical research question.
| Type of Adverse Event | Semaglutide Group (%) | Placebo Group (%) | Clinical Management Approach |
|---|---|---|---|
| Mild/Moderate Nausea | %41.2 | %13.8 | Spreading dose escalation over more flexible and longer intervals rather than 4 weeks; increasing hydration. |
| Constipation | %23.5 | %10.3 | Optimizing fiber intake and daily water consumption (at least 2 liters). |
| Episodes of Vomiting | %14.7 | %3.4 | Reducing meal portions further and following the separation of solids and liquids (the rule after bariatric surgery). |
| Dumping Syndrome / Hypoglycemia | No significant increase observed | No significant increase in the frequency of hypoglycemia or dumping syndrome after bariatric surgery was observed in the trial compared with placebo. | |
| Treatment Discontinuation Due to Adverse Effects | %5.8 (2 patients) | 3.4% (1 patient) | Acceptable rates, similar to those in the general population with obesity (STEP trials). |
⚠️ Warning About Gallstone and Pancreatitis Risk
Patients losing weight rapidly after bariatric surgery already have a high risk of developing gallstones (cholelithiasis). The period of rapid secondary weight loss achieved with semaglutide may also promote biliary sludge and gallstone formation. Patients should therefore be monitored for right upper quadrant pain during treatment, and preventive strategies should be considered by the multidisciplinary team if necessary.
Integrating the BARI-STEP data into clinical practice requires appropriate patient selection and positioning pharmacotherapy as a treatment step before invasive procedures such as revision surgery.
✓ PATIENTS TO REFER FOR MEDICAL TREATMENT (SEMAGLUTIDE)
- Timing Criterion: Patients at least 12-18 months beyond their primary surgery who have entered a defined plateau phase or whose weight loss has stopped.
- Physiological Weight Gain: Resistant cases with no anatomical defect, confirmed by endoscopy/radiology, but with uncontrolled appetite.
- Metabolic Relapse: Patients whose type 2 diabetes or insulin resistance improved after surgery but recurred with weight gain.
- High Surgical Risk: Individuals at high risk from general anesthesia and revision surgery (repeat bypass, for example).
✕ PATIENTS PRIMARILY REQUIRING SURGERY OR OTHER PROTOCOLS
- Mechanical/Anatomical Failure: Cases with excessive enlargement of the gastric pouch, a wide stoma, or a gastrogastric fistula (surgical revision or endoscopic stoma reduction takes priority).
- Early Postoperative Period: Patients within the first 12 months after surgery whose physiological weight-loss process continues steadily.
- Planned or Current Pregnancy: Semaglutide must be discontinued at least 2 months before pregnancy because of teratogenic risk; it is contraindicated in this group.
- Medullary Thyroid Carcinoma: Patients after bariatric surgery with a personal or family history of medullary thyroid cancer or MEN 2 syndrome.
Integrating medical treatments after bariatric surgery removes the polarization of obesity management into "surgery or medication?". The current approach is a model of chronic disease management in which the two methods complement each other.
ADMINISTRATION AND DOSE TITRATION PROTOCOL (Clinical Recommendations)
- Initiation and Escalation: Treatment starts with a weekly subcutaneous dose of 0.25 mg. Because of the sensitivity of the anatomy after bariatric surgery, the patient's gastrointestinal tolerance must be clearly assessed at every dose level. If symptoms develop, moving to the next dose can be delayed.
- Nutritional Integration: Semaglutide use should be combined with the fundamental discipline of bariatric surgery: "small portions, high protein, and separation of solids and liquids". Appetite suppression by the drug should not lead the patient to neglect protein intake.
- Follow-up Criteria: Regular weight monitoring, skeletal muscle preservation strategies, biochemical parameters (vitamin levels, iron, B12, HbA1c, lipid panel), and monitoring for biliary complications should be part of the routine protocol.
⚡ A SHIFT IN THE CLINICAL PARADIGM
Explaining weight gain after bariatric surgery solely in terms of behavioral nonadherence is medical reductionism. The BARI-STEP trial elucidates the neurohormonal adaptation underlying this condition. Semaglutide 2.4 mg supports clinical success by regulating hypothalamic appetite centers at the receptor level without altering the surgical anatomy.
✅ STRENGTH AND RELIABILITY OF THE EVIDENCE
BARI-STEP is an important trial that fills the evidence gap in this field with its placebo-controlled, double-blind design. The mean weight-loss outcome of - 18.0% in the treatment arm rivals the drug's effectiveness in individuals with obesity who have not undergone surgery. This indicates that tissues in patients who have undergone surgery retain their metabolic sensitivity to GLP-1 stimulation.
⚠️ CLINICAL LIMITATIONS AND CONTRADICTIONS
The main limitation of the trial is its relatively small cohort of 70 patients. This makes it difficult to clarify rare long-term adverse effects or subtle differences in response between patients with sleeve gastrectomy and those with bypass. The second issue is sustainability: how rapidly will a patient regain weight after bariatric surgery when semaglutide is discontinued? It is not yet clear how long these patients need to continue treatment.
🩺 PRACTICAL CLINICAL APPROACH
The first step in a patient beginning to gain weight after surgery is to check gastric pouch/stoma mechanics using endoscopy or a contrast transit study. If the anatomy is intact, pharmacotherapy should be considered as a priority rather than directly recommending revision surgery. Dose escalation should be managed cautiously because of the sensitivity after bariatric surgery, and the patient's adherence to the bariatric dietary regimen should be closely monitored.
❓ FUTURE QUESTIONS AWAITING ANSWERS
Will more potent combined incretins (GIP/GLP-1 dual agonists or triple agonists) be more effective than semaglutide for inadequate outcomes after bariatric surgery? Could proactive medication use in patients reaching a plateau early improve final outcomes? In cost-effectiveness analyses, will long-term pharmacotherapy or revision surgery impose a lower burden on healthcare systems?
Insufficient weight loss or weight regain developing over the long term after metabolic and bariatric surgery is a natural consequence of the chronic and relapsing nature of obesity. BARI-STEP provided randomized evidence showing that weekly semaglutide 2.4 mg achieved significant weight loss and improved metabolic parameters in this resistant patient population, with clear superiority over placebo. Once mechanical defects have been excluded in cases of inadequate outcomes after bariatric surgery, the modern algorithmic approach is not to refer patients directly for high-risk revision procedures, but to integrate new-generation pharmacotherapy options into the treatment protocol through a multidisciplinary approach.
References
- Makaronidis J, et al. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial (BARI-STEP). Nature Medicine 2026. PMID: 42174253. doi: 10.1038/s41591-026-04416-4.
- Medscape Medical News. Early Semaglutide After Bariatric Surgery Improves Outcomes: Findings from the BARI-STEP Randomised Controlled Trial. Publication Date: 8 June 2026. Available at: https://www.medscape.com/viewarticle/early-semaglutide-after-bariatric-surgery-improves-outcomes-2026a1000jkc (Accessed: 11 June 2026).
- Makaronidis J. Exploring semaglutide for post-bariatric surgery weight regain. Oral presentation at the European Association for the Study of Diabetes (EASD) Annual Congress. Abstract #1042.
- Mok J, et al. Liraglutide 3.0 mg versus placebo in individuals with poor weight loss after bariatric surgery: The BARIOPTIMISE RCT. JAMA Surg 2023;158(10):1012-1020. PMID: 37556912.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384(11):989-1002. PMID: 33567185.
- Eisenberg D, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis 2022;18(12):1474-1486. PMID: 36280459.
This article was prepared as a review of the medical literature for scientific information and does not constitute individualized treatment guidance or a clinical diagnosis. Decisions about pharmacotherapy (semaglutide, etc.) after metabolic and bariatric surgery must be made by a team comprising the patient's obesity surgeon, endocrinologist, and bariatric dietitian.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.